RxDoctor Payments Data

Kathryn Lyle

Women's Health · Birmingham, ALNPI 1649710054

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Immunogen, Inc. at 37.1% of the total. Reporting peaked in 2023 at $3,160 and has fallen 56.7% since, to $1,370 in 2025. Among women's health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,507in general payments, 2019–2025

Across 36 payments — averaging $180.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Immunogen, Inc.$2K
  • Corcept Therapeutics$1K
  • GSK$948
  • Merck$575
  • Pfizer$560
  • Clovis Oncology, Inc.$256
  • plus $655 from 6 others

What the payments were for

  • Consulting fees$2,57940%
  • Speaking & faculty fees$1,48023%
  • Travel & lodging$4837%
  • Food & beverage$1,87629%
  • Education$901%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,507 in reported general payments places this provider in the 95th percentile of 107 women's health providers in Alabama.

See all women's health providers in Alabama

Medicare billing

Part B allowed, 2024
$17,072
Medicare patients
96
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib11$113,265
EliquisApixaban49$33,256
XareltoRivaroxaban16$11,123
Estradiol28$4,569
Ondansetron Hcl53$828
Prochlorperazine Maleate67$803
Prednisolone Acetate16$575
Venlafaxine Hcl ErVenlafaxine Hcl16$378
Letrozole20$372
Sodium Chloride0.9 % Sodium Chloride27$245
Ondansetron OdtOndansetron16$210
Levothyroxine Sodium35$199
Dexamethasone12$179
Omeprazole18$137
Amlodipine Besylate28$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$37$113,26511 claims
PfizerEliquis$560$33,25649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 women's health providers in Alabama.

Other women's health in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →